Collaborations

Research collaboration to develop micro-RNA related therapies for liver cancer announced

Published in Gene Therapy Weekly, March 23rd, 2006

Isis Pharmaceuticals, Inc. (ISIS) and Rosetta Genomics Ltd., a privately held biopharmaceutical company that is developing microRNA-based diagnostic and therapeutic products, announced a joint research collaboration to discover and develop antisense drugs that regulate microRNAs (miRNAs) for the treatment of the most prevalent type of liver cancer, hepatocellular carcinoma (HCC).

The collaboration will bring together the expertise of both companies in miRNA and utilize Rosetta's database of novel miRNA genes and Isis' expertise in oligonucleotide chemistry and antisense drug discovery and development.

MicroRNAs are naturally expressed small RNAs that...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2006-03-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry